<p>Reactive Oxygen Species Modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study</p>

Abstract

Purpose: It has been reported that the overexpression of reactive oxygen species modulator 1 (Romo1) is significantly associated with poor survival outcomes in patients with lung cancer who received surgical resection, conventional fractionated radiotherapy, and chemotherapy. In this study, we investigated whether Romo1 expression is associated with survival outcomes in patients with early-stage lung cancer who were treated with radiosurgery. Methods: Romo1 protein expression was evaluated and scored in the tumor tissue specimens of 40 patients with non-small cell lung cancer by immunohistochemistry. An optimal cutoff for Romo1 expression was determined and used to allocate patients to low or high Romo1 expression groups. Survival outcomes were compared between the two groups. Results: Romo1 expression was significantly associated with distant metastasis-free survival. The 1-and 2-year distant metastasis-free survival rates were 96.4% and 92.6% in the low Romo1 expression group and 87.5% and 46.7% in the high Romo1 expression group (P=0.041), respectively. The overall, local recurrence-free, regional recurrence-free, and disease progression-free survival rates were higher in the low Romo1 expression group than the high Romo1 expression group. However, the differences were not statistically significant. Conclusion: Romo1 overexpression is associated with poor distant metastasis-free survival in patients with non-small cell lung cancer treated with radiosurgery. Further, large-scale prospective studies are required to identify the clinical efficacy of Romo1 as a potential adverse prognostic factor in lung cancer.

Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study

“… 19 , 20 According to recent studies, Romo1 was associated with early recurrence or metastasis of lung cancer treated with radiotherapy. 21 , 22 These results consistently support that Romo1 can be a promising predictive and prognostic biomarker in various treatment settings for malignancies. However, the clinical implications of serum Romo1 in patients with cancer are still unclear.…”

Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy

“…The detailed methods of initial diagnosis and pretreatment evaluation have been described in our previous studies. 17 , 18 Briefly, pretreatment evaluation consisted of complete history and physical examination, basic laboratory studies, pulmonary function test, electrocardiogram, transthoracic echocardiogram, chest radiography, chest computed tomography (CT) scan, brain magnetic resonance imaging, bone scan, and positron emission tomography (PET). The HbA1c levels of all patients were checked 1 week before the start of radiotherapy.…”

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy

“…Table 6 summarizes these previous studies and the present data, evaluating the clinical implications of Romo1 in lung cancer patients. Different studies have demonstrated different cutoffs from each other; however, the low H score cutoffs in two studies (11,30) can be attributed to the early stage population enrolled in those studies. The present data suggest that Romo1 levels seem to be abundant in advanced disease.…”

“…Romo1 is a major regulator of intracellular ROS production, and Romo1-induced ROS are indispensable for the proliferation of normal and cancer cells ( 6 , 7 ). Studies have consistently demonstrated the potential value of Romo1 as a novel biomarker for various lung cancer treatment ( 11 , 12 , 29 , 30 ). Table 6 summarizes these previous studies and the present data, evaluating the clinical implications of Romo1 in lung cancer patients.…”